CAR T-Cell Immunotherapy and Future Treatment Applications for Brain Tumor Patients

Dr. Charles Cobbs, Neurosurgeon and Director of The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at Swedish Neuroscience Institute in Seattle discusses CAR T-cell immunotherapy and its application to Brain Tumor treatment. For additional articles on this recent research for brain tumor patients, here are some additional links: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells http://www.onclive.com/publications/contemporary-oncology/2014/august-2014/chimeric-antigen-receptor-car-t-cell-immunotherapy-for-leukemia-and-beyond https://www.cirm.ca.gov/agendas/02192015/car-t-cell-immunotherapy-challenges-and-opportunities-using-mature-or-stem-memory-t

Immunocellular Therapeutics

Immunocellular Therapeutics Phase 3 ICT 107 Vaccine Clinical Trial for Glioblastoma Patients

ICT 107 is a vaccine for glioblastoma cancer stem cells.  This vaccine was developed by a company called ImmunoCellular Therapeutics, (https://www.imuc.com ) primarily by researchers at Cedars Sinai in Los Angeles.  https://virtualtrials.com/newsarticle.cfm?item=6107  This protocol has completed phase II testing and now it is open to a phase 3 randomized double blind control study for newly diagnosed glioblastoma.  […]

New High Throughput Screening Clinical Trial for Glioblastoma Brain Tumor Patients at Swedish, Seattle, WA

Swedish Medical Center in Seattle announces a clinical trial in humans for the treatment of glioblastoma, based on investigational high throughput screening of FDA-approved compounds targeting a patient’s own tumor stem cells. This trial will utilize a personalized approach for the treatment of tumor cells that have been screened against dozens of compounds, to find […]